CEO Executive AssistantHiring a full-time virtual EA for your pharmaceutical and biotech company reflects a decision that most active pharmaceutical CEOs eventually reach: that the complexity and pace of their role require consistent, comprehensive executive support rather than part-time coverage. A full-time virtual EA is not a luxury at this stage. It is an operational infrastructure investment equivalent to hiring a strong VP or director.
This guide covers when full-time is clearly the right model and how to hire for it effectively in the pharmaceutical context.
When Full-Time Virtual EA Support Is the Right Investment
The signal that part-time or shared support has become insufficient is usually not a single event. It is a pattern: routine tasks consistently overflow into your personal schedule, investor follow-ups are delayed longer than you would like, regulatory preparation windows are compressed because scheduling was not managed proactively, and you are regularly choosing between strategic work and administrative work rather than having both handled.
Specific circumstances that consistently indicate the need for full-time virtual EA support:
Phase 2 or Phase 3 Clinical Programs: CEOs at companies with mid-to-late-stage programs manage complex multi-party clinical calendars, DSMB oversight requirements, CRO management, and regulatory interaction schedules. The volume and sensitivity of this calendar work requires an EA who is fully dedicated to managing it.
Multiple Active Investor Relationships: Managing an institutional investor program with 20 or more active relationships, regular road shows, and quarterly investor updates generates administrative work that part-time support cannot sustain at the quality level your investors expect.
Active Commercial Operations: CEOs of companies with approved products add commercial operations complexity (market access, key account management, commercial team support) to the ongoing R&D and regulatory calendar. The total administrative load at this stage is clearly a full-time function.
High-Frequency Board and Governance Activity: Companies with frequent board meetings, audit committees, compensation committees, and special committee activity need an EA who has enough bandwidth to manage governance preparation without sacrificing other CEO support functions.
What Full-Time Means in Practice
A full-time virtual EA (35 to 40 hours per week) working for a pharmaceutical CEO manages:
The Complete Calendar Architecture: Not just scheduling individual meetings but managing your entire calendar ecosystem with strategic awareness. That means protecting preparation time before FDA meetings, ensuring investor road shows have appropriate recovery time, and maintaining space in your schedule for the focused thinking your role requires.
Full Investor Relations Logistics: All scheduling, briefing preparation support, conference registration, and follow-up tracking for your institutional investor program.
Board and Committee Governance: Meeting scheduling, document distribution, action item tracking, and board member logistics for all governance activities.
Travel Program Management: Complete travel logistics for all business travel, including pharmaceutical conferences, regulatory meeting travel, and investor road show logistics.
Communications Infrastructure: Inbox management, priority routing, draft correspondence for your review, and stakeholder communications management.
Regulatory Calendar Tracking: All FDA and regulatory deadline tracking, preparation time flagging, and coordination with your regulatory affairs team around CEO calendar requirements.
For a comprehensive look at the dedicated full-time service options best suited to pharmaceutical executives, see dedicated EA for pharma. For a full market comparison of virtual EA services for pharmaceutical CEOs, best virtual EA for pharma provides a detailed overview.
The Hiring Process for a Full-Time Virtual EA
Step 1: Write a Comprehensive Job Brief
For a full-time engagement, a comprehensive job brief is more important than for part-time. This document should cover: all task categories in detail, hours and availability requirements, pharmaceutical context requirements, communication standards with examples, confidentiality requirements, and the systems and tools access needed.
A well-written job brief does two things: it helps services and candidates assess fit accurately before the matching process begins, and it gives you a performance baseline against which to evaluate the relationship once it starts.
Step 2: Conduct a Thorough Service Evaluation
For a full-time engagement, invest more in the service selection process than you might for a trial or part-time arrangement. The cost is higher and the dependency is greater. Services worth evaluating:
- Request specific pharmaceutical or life sciences client references
- Ask about pharmaceutical-specific matching criteria
- Confirm that their full-time offering is truly dedicated (not shared at the full-time rate)
- Review NDA and confidentiality framework carefully with your legal team
- Understand the replacement guarantee terms in detail
Step 3: Invest in a Deep Onboarding
For a full-time EA at a pharmaceutical company, the onboarding investment is proportional to the role. Plan for 8 to 12 hours of structured onboarding across the first two weeks. This includes: regulatory calendar briefing, stakeholder introduction and context setting, communication standards review with examples, systems access and training, and information handling protocol review.
This onboarding investment is recovered within the first two months of improved EA performance.
Research from McKinsey consistently identifies onboarding quality as the primary predictor of how quickly an executive support relationship reaches full effectiveness. For full-time pharmaceutical EA engagements, where the total annual investment runs $60,000 to $100,000 or more, this onboarding investment is essential to getting the full return.
Cost Expectations for Full-Time Virtual EA Support
Full-time virtual EA support for pharmaceutical and biotech CEOs through managed services typically runs $5,500 to $9,000 per month, or $66,000 to $108,000 annually. At specialized pharmaceutical EA services, full-time support can run $8,000 to $12,000 per month.
Against the fully loaded cost of an in-house EA ($120,000 to $165,000 annually including salary, benefits, and overhead), the virtual model saves $20,000 to $60,000 per year even at the premium end, with the added benefit of replacement guarantees and no HR management overhead.
Conclusion
Hiring a full-time virtual EA for your pharmaceutical and biotech company is the appropriate investment for CEOs at companies with active clinical programs, institutional investor programs, and the full scope of regulatory and governance obligations that characterize late-stage or commercial pharmaceutical operations. Hire through a managed service with pharmaceutical client experience, invest in a comprehensive onboarding, and expect full operational effectiveness by month two to three. The leverage a well-matched full-time EA creates at a pharmaceutical company justifies the investment within the first quarter.
Related Reading
For further context, explore Hire a Full-Time Virtual EA for Your Automotive Company and Hire a Full-Time Virtual EA for Your Construction & Architecture Company.